Effect of N,N,N,-trimethylsphingosine on protein kinase C activity melanoma cell growth in vitro; metastatic potential in vivo and human platelet aggregation
AssigneeThe Biomembrane Institute
InventorsYasuyuki Igarashi, Mahammad N. Ahmad, Hirofumi Okoshi, Sen-Itiroh Hakomori
Life of this patent
Estimating the term…
Abstract
The invention relates to a novel compound, compositions and medicaments thereof and a method of inhibiting cell proliferation, platelet aggregation (induced by various factors), and inhibiting malignant phenotypes of tumor cells such as those having a metastatic property, using said compound, composition or medicament. N,N,N-trimethylsphingosine shows superior cell proliferation inhibitory and anti-metastatic activity over related compounds.
Claims20
N,N,N-trimethylsphingosine.
A pharmaceutically acceptable salt of N,N,N-trimethylsphingosine.
A medicament comprising:
- (a) a cell proliferation inhibiting amount of N,N,N-trimethylsphingosine or pharmaceutically acceptable salt thereof;
- and
- (b) a pharmaceutically acceptable carrier, diluent or excipient.
A composition comprising:
- (a) a cell proliferation inhibiting amount of N,N,N-trimethylsphingosine;
- and
- (b) a carrier, diluent or buffer.
A method for inhibiting cell proliferation comprising contacting cells with a cell growth inhibitory amount of N,N,N-trimethylsphingosine.
An N,N,N-trimethylsphingosine made by the process comprising the steps of:
- (a) dissolving (4E)-N,N-dimethyl-D-erythro-sphingosine in an anhydrous organic buffer to produce a solution;
- (b) dissolving in said solution of step (a) freshly distilled iodomethane to produce a mixture;
- (c) incubating said mixture of step (b) to produce a N,N,N-trimethylsphingosine product;
- and
- (d) separating said N,N,N-trimethylsphingosine produced therefrom.
A method of inhibiting platelet aggregation comprising exposing platelets to an aggregation inhibiting amount of N,N,N-trimethylsphingosine.
A medicament comprising:
- (a) a platelet aggregation inhibiting amount of N,N,N-trimethylsphingosine or pharmaceutically acceptable salt thereof;
- and
- (b) a pharmaceutically acceptable carrier, diluent or excipient.
A composition comprising:
- (a) a platelet aggregation inhibiting amount of N,N,N-trimethylsphingosine;
- and
- (b) a carrier, diluent or buffer.
A therapeutic method comprising administering to a host in need of treatment a cell proliferation inhibiting amount of N,N,N-trimethylsphingosine or a pharmaceutically acceptable salt thereof.
A therapeutic method comprising administering to a host in need of treatment a platelet aggregation inhibiting amount of N,N,N-trimethylsphingosine or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.